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Advanced aging, vascular dysfunction, and nitric oxide (NO) bioavailability are recognized
risk factors for Alzheimer’s disease (AD). However, the contribution of AD, per se, to this
putative pathophysiological mechanism is still unclear. To better answer this point, we
quantified cortical perfusion with arterial spin labeling (PVC-CBF), measured ultrasound
internal carotid (ICA), and femoral (FA) artery blood flow in a group of patients with similar
age (∼78 years) but different cognitive impairment (i.e., mild cognitive impairment MCI,
mild AD-AD1, moderate AD-AD2, and severe AD-AD3) and compared them to young
and healthy old (aged-matched) controls. NO-metabolites and passive leg-movement
(PLM) induced hyperemia were used to assess systemic vascular function. Ninety-eight
individuals were recruited for this study. PVC-CBF, ICA, and FA blood flow were markedly
(range of 9–17%) and significantly (all p < 0.05) reduced across the spectrum from YG
to OLD, MCI, AD1, AD2, AD3 subjects. Similarly, plasma level of nitrates and the values
of PLM were significantly reduced (range of 8–26%; p < 0.05) among the six groups.
Significant correlations were retrieved between plasma nitrates, PLM and PVC-CBF, CA,
and FA blood flow. This integrative and comprehensive approach to vascular changes in
aging and AD showed progressive changes in NO bioavailability and cortical, extracranial,
and peripheral circulation in patients with AD and suggested that they are directly
associated with AD and not to aging. Moreover, these results suggest that AD-related
impairments of circulation are progressive and not confined to the brain. The link between
cardiovascular and the central nervous systems degenerative processes in patients at
different severity of AD is likely related to the depletion of NO.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of
dementia, with an attested prevalence of ∼24 million which
is predicted to quadruplicate by 2050 (Reitz et al., 2011).
Pathophysiological mechanisms of AD are well-defined,
including diffuse neuritic extracellular amyloid (Aβ) plaques
and intracellular neurofibrillary tangles coupled with reactive
microgliosis, loss of neurons and synapses in the cortex (Reitz
and Mayeux, 2014). From the vascular point of view, Aβ
peptide accumulation in the tunica media and adventitia of
cerebral blood vessels, a condition termed cerebral amyloid
angiopathy (CAA), is associated with vessel smooth muscle cell
degeneration, resulting in impaired cerebral circulation (Maier
et al., 2014).
Apart from this direct effect of Aβ accumulation in the cortical
neurons and vessels, there is increasing evidence that AD is
associated with several dysregulated processes, which affect brain
and systemic circulation, suggesting that vascular dysfunction
may play a role in the pathogenesis of AD (Iturria-Medina
et al., 2016). These pieces of evidence pose the question whether
AD is an age-related neurodegenerative disorder with vascular
consequences, or a vascular disorder with neurodegenerative
sequels (De La Torre, 2010). Indeed, both aging and AD appear
to be involved in the decline of the systemic and cerebral vascular
function (De La Torre, 2009). However, the contribution of
AD, per se, to vascular changes is still unclear. Additionally, the
cardiovascular and the central nervous system (CNS) changes
have been postulated to occur in parallel during the progression
of AD (Picano et al., 2014).
In the brain of patients with AD, diffuse cortical changes
have been demonstrated (Dallaire-Theroux et al., 2017), coupled
with a reduced perfusion of the temporo-parietal association
cortices, mesial temporal structures and the frontal association
cortex (Herholz, 2011). However, potential reduction of blood
flow availability inward from extracranial conduit arteries
(i.e., internal carotid artery (ICA), vertebral artery) may also
contribute to the onset of AD (Liu et al., 2014; Clark et al.,
2017). In this scenario, nitric oxide (NO) is considered the most
important vasodilator factor responsible for the preservation of
vasomotor function (Katusic and Austin, 2014). Indeed, reduced
availability of NO in both cerebral and peripheral vessels results
in major detrimental alterations of vascular function (Katusic
and Austin, 2014). However, the role of NO bioavailability in
the control of extracranial blood flow, cerebral, and systemic
circulation in patients with different AD severity have not been
so far fully elucidated.
Therefore, the aims of the present study were two-fold.
The first was to evaluate if the NO bioavailability, cerebral
perfusion, extracranial, peripheral blood flow and systemic
vascular function are reduced in AD in comparison to healthy
young and old individuals. The second was to compare these
measures in patients with different AD severity. Specifically, we
have assessed cortical perfusion with arterial spin labeling (ASL)
Magnetic Resonance Imaging (MRI), and measured ICA and
femoral (FA) artery blood flow in young (YG) and old (OLD)
healthy controls, patients with mild cognitive impairment (MCI)
and AD of different severity: mild AD (AD1), moderate AD
(AD2), and severe AD (AD3). NO bioavailability was determined
in the six groups via plasma NOmetabolites (nitrite and nitrate).
Passive leg-movement (PLM) induced hyperemia was used to
assess both endothelial NO availability and systemic vascular
function. We hypothesized that (a) the severity of AD would
impact on cortical perfusion, as well as ICA and FA blood flow,
and (b) brain and systemic impairment of circulation would be
associated with a depletion of NO bioavailability.
METHODS
Participants
Patients with MCI and AD were recruited from the Neuromotor
and Cognitive Rehabilitation Research Center Azienda
Ospedaliera Universitaria Integrata of Verona, and the Geriatric
Institute Mons. Arrigo Mazzali Foundation (Mantua, Italy).
Clinical diagnosis of MCI and probable AD was established
according to the National Institute on Aging-Alzheimer’s
Association diagnostic guideline for MCI due to AD and AD
(Albert et al., 2011; Mckhann et al., 2011). All patients had
a previous neuroimaging study (MRI or CT) to support the
diagnosis of MCI and/or probable AD.
Dementia severity was assessed by means of the Mini Mental
State Examination (MMSE) (Folstein et al., 1975) and the
Clinical Dementia Rating scale (CDR) (Morris, 1993). According
to the severity of dementia, patients with AD were divided
in three groups: AD1 with MMSE scores between 20 and
24 and CDR 1, AD2 with MMSE scores between 10 and
19 and CDR 2, and AD3 with MMSE scores lower than 10
and CDR 3. Two additional healthy control groups (i.e., YG
and OLD) were recruited from the same geographical area,
after a physician’s assessment of negligible cardiovascular and
musculoskeletal diseases. This screening included health history,
physical examination, blood pressure assessment, blood sample,
and familiarization with the study procedures. OLD had to have
a MMSE ≥ 24. As reported in the AD diagnostic guidelines
(Mckhann et al., 2011), individuals with a diagnosis of vascular
dementia (VaD) were not included in the study. Other exclusion
criteria were: history of depression or psychosis, alcohol or drug
abuse, other neurological (e.g., Parkinson’s disease, traumatic
brain injury, stroke, multiple sclerosis), cardiac, orthopedic
(e.g., osteoarthrosis) or respiratory conditions (e.g., chronic
obstructive pulmonary disease). All experiments were conducted
after informed and written consent was obtained from the
patients and their relatives and healthy individuals in accordance
with the Declaration of Helsinki, as part of a protocol approved
by the Institutional Review Board of the Azienda Ospedaliera
Universitaria Integrata (Approval #2389).
Assessment Procedure
Neurologists and clinical neuropsychologists with a specific
expertise in dementia investigated the cognitive profile of the
patients with a full neuropsychological profile and the following
tests were performed. The MMSE (Folstein et al., 1975) was
used to assess the global cognitive status. The CDR (Morris,
1993) scale was administered to quantify the severity of dementia.
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The Italian version of the Frontal Assessment Battery (FAB)
(Appollonio et al., 2005) was used to assess executive functions.
Level of Physical Activity
The International Physical Activity Questionnaire (IPAQ)
(Booth, 2000) was used to estimate the level of physical activity of
the participants. Each question was administered to the healthy
volunteers and to the patient’s caregivers.
Volume Anthropometry Assessment
Thigh and lower leg volume were calculated based on leg
circumferences (three sites: distal, middle, and proximal), thigh
and lower leg length, and skinfold measurements using the
following formula:
V =
L
12π
·
(
C12 + C22 + C32
)
−
S− 0.4
2
· L ·
C1+ C2+ C3
3
where L refers to the length; C1, C2, and C3 refer to the proximal,
middle, and distal circumferences, respectively; and S is skinfold
thickness of either the thigh or the lower leg. The length of
the leg was measured from the greater trochanter to the lateral
femoral epicondyle (thigh) and from the head of the fibula to
the lateral malleolus (lower leg). The length and circumference
were measured to the nearest 1mm using a flexible standard
measuring tape. Skinfold thickness was measured using skinfold
calipers (Beta Technology Incorporated, Cambridge, MD) at
three sites at the midpoint of each limb segment (Layec et al.,
2014).
Resting Oxygen Uptake Assessment
Briefly, oxygen uptake was recorded with the subjects supine
and at rest for 20min. Expired gases were analyzed on a breath-
by-breath basis by a metabolimeter (K4 b2, Cosmed, Rome,
Italy).
Cortical Perfusion Assessment
A subgroup of the total population underwentMRI to assess non-
invasively cerebral blood flow (CBF) with ASL (Detre et al., 1992).
In details, forty-three subjects (YG: 10, OLD: 7, MCI: 6, AD1: 5,
AD2: 9, AD3: 6) were scanned on a 3T Philips Achieva system
equipped with an 8-channel head coil. They were instructed to
lie as still as possible in the scanner, to keep their eyes closed
but not to fall asleep while images were collected. For ASL data,
pseudo-continuous (pCASL) labeling was acquired using the
following parameters: TR/TE= 4,400/11ms; label duration/post-
label delay= 1,650/1,800ms; 45 Control/Label volumes; 26 slices,
3 × 3 × 3 mm3, slice gap = 1mm; two background suppression
pulses at 1,700 and 2,926ms from the start of the scan. A
calibration scan with the same parameters as the ASL sequence
but longer TR (10 s) and no background suppression was also
acquired to estimate the equilibriummagnetization. Finally, a 3D
T1-weighted turbo field echo anatomical scan was also acquired
for each subject (TR/TE = 8.16/3.73ms; 180 slices, 1 × 1 × 1
mm3).
ASL data were preprocessed and analyzed using FSL 5.0.9
(FMRIB, Oxford, UK) and Matlab 7.14 (MathWorks, Natick,
MA). ASL data were first corrected for nuisance effects (head
motion profiles, cerebrospinal fluid (CSF) and white matter
(WM) signals) by using linear regression that minimizes the
sum of squares of the residuals. The ASL calibration scan was
used for estimating the coregistration parameters from ASL to
the individual T1-weighted image by applying a 3D rigid-body
registration with a normalized mutual-information cost function
and 7 degrees of freedom.
Pre-processed Control and Label volumes were then surround
subtracted and averaged to obtain perfusion-weighted images.
These perfusion-weighted maps were quantified into CBF
[ml/100 g/min] applying the general kinetic model (Buxton et al.,
1998) as follows:
CBF =
6000 · λ ·1M · e
PLD
T1b
2 · α · αinv · T1b ·M0t · (1− e
− τT1b )
where λ is the brain-blood partition coefficient (0.9 mL/g),
1M represents the difference images (perfusion-weighted maps),
PLD is the post-labeling delay, T1b is the longitudinal relaxation
time of arterial blood (1,650ms), α is the labeling efficiency (0.85
for pCASL), where αinv corrects for the decrease in labeling
efficiency due to two background suppression pulses (0.83). M0t
is the tissue equilibrium magnetization, voxel-wise estimated
from the calibration scan, and τ represents the labeling duration
(Alsop et al., 2015). The increase in label decay in the ascending
slices acquired with 2D readout was accounted for.
In order to perform partial volume effects-correction (PVC)
mainly related to the low ASL spatial resolution and brain
atrophy, partial volume-corrected cortical and WM flow maps
were created for each subject. In details, high resolution gray
matter (GM) and WM probability maps from the segmentation
of the 3D T1-weighted image were first smoothed with a 3 × 3
× 3 mm3 kernel to mimic the ASL resolution. These smoothed
maps were then down sampled to the ASL space using the inverse
of the previously estimated transformation matrix and finally
applied to the CBF maps for PVC following the equation Icorr
= Iuncorr/(Pgm + 0.4·Pwm) (Du et al., 2006). For each subject, the
mean corrected CBF value within the GM mask was calculated
and used as individual representative measure of the whole
cortical perfusion.
To provide group CBF maps, individual T1-weighted images
were registered to the Montreal Neurological Institute (MNI)
space with 1× 1× 1 mm3 resolution using a non-linear method
(FNIRT tool in FSL) and the joint ASL/T1-weighted and T1-
weighted/MNI space transformation parameters were used to
spatially normalize the subject specific CBFmaps in this common
space. Representative mean uncorrected (whole brain) and PVC
cortical (GM only) CBF maps in MNI space were finally derived
for each of the six groups.
ICA and FA Blood Flow Assessment With
Doppler Ultrasound Imaging
ICA, and FA artery diameters and blood velocities were recorded
with the subjects supine and at rest for 20min. When the blood
flow was stable, 1-min video of the above-mentioned arteries
was recorded on the ultrasound system. Specifically, the Doppler
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probe was positioned at the level of ICA ∼1 cm above the
common carotid bifurcation, and at the level of the common
FA, distal to the inguinal ligament and proximal to the deep
and superficial femoral bifurcation. Triplex Doppler clips were
recorded with a Logiq-7 ultrasound Doppler system (General
Electric Medical Systems, Milwaukee, WI, USA). The ultrasound
Doppler system was equipped with a 12-14 MHz linear array
transducer. Artery diameter was determined at a 90◦ angle along
the central axis of the scanned area. Blood velocity (Vmean)
was measured using the same probe utilizing a frequency of 5
MHz. Measurements of Vmean were obtained with the probe
positioned to maintain an insonation angle of 60◦ or less and
the sample volume was centered and maximized according to
vessel size. Utilizing arterial diameter and Vmean, blood flow was
calculated as:
Blood flow = Vmean · pi·(vessel diameter/2)
2 ·60
where blood flow is in milliliters per minute. To perform muscle
and brain volume effect-corrections, mostly related to the lower
limb muscle and brain atrophy, FA and ICA blood flow were
normalized to leg muscle volume (thigh + lower leg volume)
and total brain tissue volume (cortical, subcortical GM and WM
volumes, including the brainstem and cerebellum), respectively
(Liu et al., 2014; Venturelli et al., 2014). All scanning and
blinded analyses were performed by experienced and skilled
sonographers.
NO Bioavailability via Plasma Nitrates
Assessments
It is important to note, that all the participants were asked
to refrain from oral intake of supplements or nutrients with
elevated levels of nitrates. Specifically, on the 3 days before
the assessments strawberries, lettuce, beets, and carrots were
not included in the participants diet. Venous peripheral blood
(25mL) was collected between 9:00 and 10:00 am from patients
and healthy controls in a fasted state and processed within
2 h to obtain measurements of blood glucose, number of
red blood cells (RBC), hemoglobin (Hb), high- and low-
density lipoprotein (HDL, LDL). From a different vacutainer,
plasma was separated from peripheral blood by centrifugation
(1,200 rpm for 20min at 4◦C) and kept at −80◦C until
analysis. Plasma samples were ultrafiltrated through a 30 kDa
molecular weight cut-off filter (cat. No UFC503096) (Millipore,
Molseheim, France) to reduce background absorbance. Nitrate
concentration was detected by nitrate/nitrite colorimetric assay
kit (cat. No 780001) (Cayman Chemical Co, Ann Arbor, MI,
USA) according to the manufacturer’s protocol. The detection
limit of nitrate was 2.5µM. The nitrate concentration was
analyzed in duplicate and read against themanufacturer standard
curve.
Endothelial NO Bioavailability and
Systemic Vascular Function via PLM
Recent investigations have revealed that PLM-induced
hyperemia is predominantly a consequence of NO mediated
vasodilation (Trinity et al., 2012). Therefore, we have adopted
this noninvasive and reliable method to determine endothelial
NO bioavailability. Moreover, the PLM protocol has been
successfully adopted to determine systemic vascular function
in healthy young (Mcdaniel et al., 2010a), elderly (Mcdaniel
et al., 2010b), patients with spinal cord injury (Venturelli et al.,
2014), and heart failure (Ives et al., 2016). During this evaluation,
the subjects rested in the upright-seated position for 20min
before the start of data collection and remained in this position
throughout this part of the study. The PLM protocol consisted
of 60 s of resting baseline femoral blood flow data collection,
followed by 60 s of passive knee extension and flexion with the
same measure. PLM was performed by a member of the research
team, who moved the subject’s lower leg through a 90◦ range
of motion (180-90◦ knee joint angle) at 1Hz. Blood Vmean was
analyzed with 1Hz resolution on the Doppler ultrasound system
(GE Logiq-7) for 60 s at rest and second by second for the first
60 s following the initiation of PLM. Relative changes (1peak)
from rest of femoral blood flow was determined for each subject.
To perform muscle volume effect-correction related to the
skeletal muscle atrophy, 1peak blood flow was normalized by
thigh muscle volume (Venturelli et al., 2014).
Data Analysis and Interpretation
The representative outcomes from each assessment were
analyzed using a statistical software package (StatPlus:mac,
AnalystSoft Inc.,-statistical analysis program for Mac OS R©.
Version v6.). The normal distribution of the sampling was
checked by the Shapiro-Wilk test. A one-way analysis of variance
(ANOVA), and, where indicated, a Tukey post hoc test, were used
to determine the group differences. A chi-square (χ2) analysis
was used to establish differences between categorical variables.
Pearson correlation test was used to examine the correlation
between variables. Significance was set at an α level of 0.05
(two-tailed), and the results are presented as mean± SE.
RESULTS
Characteristics of the Participants
Demographic and clinical characteristics of the study participants
are displayed in Table 1. Ninety-eight individuals (YG:10,
OLD:14, MCI:19, AD:55) were recruited for this study. Except for
the YG, all groups were matched for age, sex, body mass, thigh
muscle volume, lower leg muscle volume, coexisting chronic
conditions. Drugs for AD and other medications taken by the
four groups of MCI/AD patients and the two groups of healthy
individuals are displayed in Table 1.
Resting Metabolism, and Level of Physical
Activity
Resting oxygen uptake, expired carbon dioxide (ExpCO2) and
the values of IPAQ, taken as marker of basal metabolism and
level of physical activity, respectively, are illustrated in Table 1.
Interestingly, any statistical difference was retrieved among
the six groups in terms of basal metabolism (all p > 0.2).
In comparison to the YG, the level of physical activity was
significantly reduced in OLD (p < 0.01), MCI (p < 0.01), AD1
(p < 0.01), AD2 (p < 0.01), and AD3 (p < 0.01). However, the
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TABLE 1 | Demographic and clinical characteristics of the study participants.
YG (N = 10) OLD (N = 14) MCI (N = 19) AD1 (N = 24) AD2 (N = 20) AD3 (N = 11)
Sex 4♂-6♀ 6♂-6♀ 9♂-10♀ 9♂-15♀ 6♂-14♀ 2♂-9♀
Age (years) 28 ± 2 76 ± 6* 77 ± 4* 78 ± 7* 80 ± 8* 80 ± 7*
Weight (kg) 68 ± 20 73 ± 12 75 ± 19 63 ± 12 73 ± 13 62 ± 4§
Height (m) 1.69 ± 0.3 1.67 ± 0.1 1.65 ± 0.1 1.58 ± 0.1 1.62 ± 0.1 1.62 ± 0.2
Lower limb volume (l) 8.3 ± 1.7 8.3 ± 1.5 7.8 ± 1.6 7.4 ± 1.4 7.4 ± 1.1 7.3 ± 1.3
Thigh volume (l) 5.9 ± 1.5 6.2 ± 1.3 5.7 ± 1.4 5.4 ± 0.9 5.1 ± 2.0 5.3 ± 1.3
Leg volume (l) 2.4 ± 0.7 2.1 ± 0.6 2.1 ± 0.9 2.0 ± 0.5 2.3 ± 1.1 2.0 ± 0.7
SBP (mm Hg) 118 ± 20 129 ± 33 136 ± 37 132 ± 12* 130 ± 9* 125 ± 9*
DBP (mm Hg) 85 ± 10 90 ± 24 92 ± 12 86 ± 10 90 ± 5 82± 10
Glucose (mg·dl−1) 88 ± 12 95 ± 32 107 ± 21* 91 ± 8§ 95 ± 47§ 89 ± 15§
RBC (106·µl−1 ) 5.2 ± 0.9 5.0 ± 0.6 4.8 ± 0.4 4.8 ± 0.6 4.5 ± 0.5*†§ 4.3 ± 0.3*†§
Hb (g·dl−1) 15 ± 2 15 ± 3 13 ± 1*† 13 ± 2*† 13 ± 2*† 12 ± 0.6*†
HDL (mg·dl−1) 49 ± 24 50 ± 17 58 ± 19 57 ± 21 57 ± 11 64± 17*†‡¶
LDL (mg·dl−1) 99 ± 30 100 ± 23 102 ± 15* 122 ± 32*§ 110 ± 12*‡ 136 ± 18*§
Education (years) 19 ± 2 10 ± 6* 10 ± 4* 9 ± 5* 7 ± 4* 7 ± 4*
IPAQ (METs·min·week−1 ) 12,340 ± 832 4,043 ± 548* 3,874 ± 655* 4,129 ± 438* 3,784 ± 732* 3,833 ± 543*
Resting oxygen uptake (ml·m−1·kg−1 ) 4.4 ± 1.8 3.9 ± 1.8 3.6 ± 1.1 4.5 ± 1.2 3.5 ± 1.8 3.7 ± 1.5
ExpCO2 (ml) 27.5 ± 7.8 23.2 ± 9.2 17.8 ± 9.8 21.9 ± 14.3 15.0 ± 5.5 19.5 ± 7.8
CLINICAL CHARACTERISTICS
Time since diagnose of MCI or AD (years) – – 2 ± 1 6 ± 2 § 8 ± 3§‡ 8 ± 2§‡
MMSE (0-30) – 28 ± 1 27 ± 2† 22 ± 3†§ 16 ± 3†§‡ 11 ± 4*†§‡¶
CDR (0-3) – – 0.5 1§ 2§‡ 3§‡¶
FAB (0-18) – – 12 ± 2 9 ± 3§ 8 ± 3§ 4 ± 4§‡¶
PHARMACOLOGICAL TREATMENT n. (%)
Cholinesterase Inhibitors 0 0 2 (10) 10 (42)*† 5 (25)*† 3 (27)*†
Antipsychotics 0 0 0 1 (4) 1 (5) 1 (9)
Antidepressants 0 0 0 2 (8) 4 (20)*† 2 (18)*†
Benzodiazepines 0 0 0 0 1 (5) 1 (5)
COMORBIDITY n. (%)
Cardiovascular diseases 0 0 1 (5) 4 (16)*† 2 (10)*† 3 (27)*†
Diabetes 0 0 1 (5) 0 1 (5) 1 (9)
Arthrosis 0 0 1 (5) 2 (8) 1 (5) 1 (9)
♂, male; ♀, female; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; RBC, red blood cells; Hb, hemoglobin; HDL,
high-density lipoprotein; LDL low-density lipoprotein; IPAQ, international physical activity questionnaire; ExpCO2, expired carbon dioxide; MET, metabolic equivalent; MMSE, Mini Mental
State Examination; CDR, Clinical Dementia Rating Scale; FAB, Frontal Assessment Battery. Values are expressed as mean ±standard deviation (or percentage in brackets). *p < 0.05
vs. YG;
†
p < 0.05 vs. OLD; §p < 0.05 vs. MCI; ‡p < 0.05 vs. AD1; ¶p < 0.05 vs. AD2.
differences in IPAQ values among OLD, MCI, AD1, AD2, and
AD3 were not significant and negligible.
Cortical Perfusion
Representative mean CBF images for the six groups are shown
in Figure 1, reporting both whole brain uncorrected (Figure 1A)
and PVC cortical (Figure 1B) CBF maps at the same anatomical
level. As clearly visible, there was a marked and progressive
reduction in the CBF parameter, confirmed after PVC, across the
spectrum from YG to OLD, MCI, AD1, AD2, and AD3 subjects.
Quantitative analysis supported these visual impressions (p <
0.05 among the six groups) with average PVC-CBF levels of 57.7
± 1.7 ml·100 g−1·min−1 in YG, 48.6 ± 1.0 ml·100 g−1·min−1
in OLD, 44.7 ± 1.0 ml·100 g−1·min−1 in MCI, 40.8 ± 2.0
ml·100 g−1·min−1 in AD1, 34.5 ± 1.5 ml·100 g−1·min−1 in
AD2, and 30.1 ± 2.5 ml·100 g−1·min−1 in AD3 and significant
post-hoc comparisons across MCI and different AD stages
(Figure 1C).
ICA Blood Flow
Resting blood flow in the ICA normalized to total brain tissue
volume, taken as marker of extracranial blood flow, is illustrated
in Figure 2. Among the six groups there was a progressive
significant reduction in ICA blood flow (p < 0.05). Specifically,
blood flow in the ICA was 0.34 ± 0.02 ml·min−1·100 ml−1
in YG, 0.30 ± 0.03 ml·min−1·100 ml−1 in OLD, 0.24 ± 0.01
ml·min−1·100 ml−1 in MCI, 0.22 ± 0.01 ml·min−1·100 ml−1
in AD1, 0.20 ± 0.01 ml·min−1·100 ml−1 in AD2, and 0.17 ±
0.01 ml·min−1·100 ml−1 in AD3 subjects (Figure 2). Post-hoc
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FIGURE 1 | Cortical perfusion data. (A) Group whole brain uncorrected
cerebral blood flow (CBF) maps, calculated as average across the individual
subjects belonging to healthy young (YG) and healthy old (OLD) controls,
patients with mild cognitive impairment (MCI) and with different severity of AD,
namely mild AD (AD1), moderate AD (AD2), and severe AD (AD3). Two
representative sections are reported for each of the three views (axial, coronal,
and sagittal). (B) Group mean cortical CBF maps after partial volume
correction (PVC cortical), reported for the same anatomical levels as before.
(C) reports group mean PVC cortical CBF levels (mean ± S.E). *Significantly
different vs. YG group; †Significantly different vs. OLD group. ‡Significantly
different vs. MCI group. §Significantly different vs. AD1 group. #Significantly
different vs. AD2 group.
comparisons were significant across MCI and different AD
stages.
FA Blood Flow
Resting blood flow in the FA normalized to the lower limbmuscle
volume, is illustrated in Figure 3. With a similar trend of the ICA
blood flow, the FA hemodynamic was significantly attenuated (p
< 0.05) compared to the YG (45 ± 2 ml·min−1·l−1) in the OLD
(39 ± 3 ml·min−1·l−1) and even more so in the MCI, AD1, AD2
and AD3 (35 ± 2 ml·min−1·l−1, 31 ± 3 ml·min−1·l−1, 27 ± 3
ml·min−1·l−1, and 23± 2 ml·min−1·l−1) respectively (Figure 3).
Post-hoc comparisons were significant across MCI and different
AD stages.
NO Bioavailability and Systemic Vascular
Function
Plasma levels of nitrates and PLM induced hyperemia, which
were used as markers of NO bioavailability and systemic vascular
FIGURE 2 | Internal carotid artery blood flow normalized to brain volume.
Internal carotid artery (ICA) blood flow normalized to brain volume in healthy
young (YG) and healthy old (OLD) controls, patients with mild cognitive
impairment (MCI), and with different severity of AD, namely mild AD (AD1),
moderate AD (AD2), and severe AD (AD3). Data are presented as mean ±S.E.;
*significantly different vs. YG group. †Significantly different vs. OLD group.
‡Significantly different vs. MCI group. §Significantly different vs. AD1 group.
#Significantly different vs. AD2 group.
FIGURE 3 | Femoral artery blood flow normalized to muscle limb volume.
Femoral artery (FA) blood flow normalized for lower limb muscle volume in
healthy young (YG) and healthy old (OLD) controls, patients with mild cognitive
impairment (MCI), and with different severity of AD, namely mild AD (AD1),
moderate AD (AD2), and severe AD (AD3). Data are presented as mean ±S.E.;
*Significantly different vs. YG group. †Significantly different vs. OLD group.
‡Significantly different vs. MCI group. §Significantly different vs. AD1 group.
#Significantly different vs. AD2 group.
function, are illustrated in Figure 4. Both these markers of
NO bioavailability showed a clear and progressive reduction
across the groups. Specifically, plasma level of nitrates was
significantly reduced (p < 0.05) from YG to OLD, MCI and
through AD stages, with values of 67.8 ± 4.2µM in the YG,
58.1 ± 5.1µM in OLD, 51.1 ± 3.0µM in MCI, 45.1 ± 3.7µM
in AD1, 39.2 ± 3.7µM in AD2, and 36.1± 23.3µM in AD3
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FIGURE 4 | Nitric oxide bioavailability and systemic vascular function. Nitric
oxide (NO) bioavailability was determined by plasma levels of nitrates (A) and
passive limb movement induced hyperemia normalized for muscle volume
(1PLM; B). Systemic vascular function determined via 1PLM/muscle volume
is represented in (B) in healthy young (YG) and healthy old (OLD) controls,
patients with mild cognitive impairment (MCI), and with different severity of AD,
namely mild AD (AD1), moderate AD (AD2), and severe AD (AD3). Data are
presented as mean ±S.E.; *Significantly different vs. YG group. †Significantly
different vs. OLD group. ‡Significantly different vs. MCI group. §Significantly
different vs. AD1 group. #Significantly different vs. AD2 group.
(Figure 4A). Similarly, 1PLM hyperemia normalized for the
muscle volume was significantly reduced (p < 0.05) among the
6 groups, with values of 45 ± 2 ml·min−1·l−1 in YG, 36 ± 3
ml·min−1·l−1 in OLD, 30 ± 2 ml·min−1·l−1 in MCI, 27 ± 2
ml·min−1·l−1 in AD1, 20 ± 3 ml·min−1·l−1 in AD2, and 16
± 2 ml·min−1·l−1 in AD3 (Figure 4B). Post-hoc comparisons
were significant across MCI and different AD stages for both
measures.
Correlation Between NO Bioavailability,
Systemic Vascular Function and Cortical,
Extracranial, and Peripheral Blood Flow
Correlations between plasma levels of nitrates, PLM-induced
hyperemia, which were used as markers of NO bioavailability
and systemic vascular function, cortical perfusion, extracranial
blood flow, and peripheral circulation are illustrated in Figure 5.
Specifically, significant correlations were found between plasma
levels of nitrates and FA blood flow normalized to the limb
muscle volume (Figure 5A; r = 0.48, p < 0.05), ICA blood flow
normalized for brain volume (Figure 5C; r = 0.61, p < 0.05),
and PVC–CBF (Figure 5E; r = 0.45, p < 0.05). Interestingly,
also values of1PLM/muscle volume were significantly correlated
with FA blood flow/muscle volume (Figure 5B; r = 0.71, p <
0.05), ICA blood flow/brain volume (Figure 5D; r = 0.82, p <
0.05), and PVC–CBF (Figure 5F; r = 0.77, p< 0.05).
DISCUSSION
Although the association between reduction of NO
bioavailability, cortical hypoperfusion and systemic vascular
dysfunction has been already investigated in relation to AD onset
in murine models, the mechanistic role of NO depletion in the
reduction of extracranial blood flow and impairment of cortical
and peripheral circulation in humans with AD has received so far
only little attention. In the present study, we assessed ICA blood
flow, cortical perfusion, and peripheral circulation in patients
with MCI and different stages of AD and compared them to
young and old healthy controls. Additionally, NO bioavailability
was determined in the six groups of participants via plasma NO
metabolites. A further indicator of endothelial NO bioavailability
and systemic vascular function was estimated with PLM induced
hyperemia. The main finding of this study was that ICA blood
flow, cortical perfusion, peripheral circulation, and systemic
vascular function were reduced in OLD vs. YG controls, and
progressively further decreased in parallel to MCI and AD
severity. These data suggest a pivotal role of AD, per se, to
these vascular abnormalities. Though the causative relationship
between NO bioavailability, central and peripheral circulation is
still matter of debate, according to our hypothesis, circulation
impairment was associated with NO depletion (Figures 5, 6).
Evidence That AD, per se, Affects NO
Bioavailability and Blood Flow
Indeed, the first risk factor for AD is advanced age (Reitz
et al., 2011; Reitz and Mayeux, 2014). It should also be noted
that, independent of AD, reduced availability of NO, which
is dramatically decreased in the aged population, results in
major detrimental alterations of vascular function, including
vasoconstriction and hypertension, leading to atherosclerosis. On
the other hand, recent literature highlighted that AD is highly
correlated to systemic vascular dysfunction (Iturria-Medina
et al., 2016). Interestingly, current literature suggests the key
role of NO depletion in the pathogenesis of neurodegenerative
disease (Katusic and Austin, 2014). Therefore, we may speculate
that both age and AD appear to be involved in the decline
Frontiers in Physiology | www.frontiersin.org 7 March 2018 | Volume 9 | Article 169
Venturelli et al. NO and Circulation in AD
FIGURE 5 | Correlations between nitric oxide bioavailability, systemic vascular function and cortical (PVC–CBF), internal carotid artery (ICA) and femoral artery (FA)
blood flow normalized for brain and muscle volume, respectively. Nitric oxide (NO) bioavailability was determined by plasma levels of nitrates (A,C,E) and passive limb
movement induced hyperemia normalized to muscle volume (1PLM; B,D,F). Systemic vascular function determined via 1PLM/muscle volume is represented in B,D,F
in healthy young (YG) and healthy old (OLD) controls, and patients with mild cognitive impairment (MCI), and with different severity of AD, namely mild AD (AD1),
moderate AD (AD2), and severe AD (AD3). Each point represents a single subject, dashed lines represents interval of confidence.
of the systemic and cerebral vascular function likely because
of endogenous NO reduced bioavailability. However, the
contribution of AD, per se, to this putative pathophysiological
mechanism is still unclear. To better answer this point, we
explored NO bioavailability, and cortical, ICA and peripheral
blood flow in a group of patients with similar age (∼78
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FIGURE 6 | schematic illustration: Impact of nitric oxide bioavailability on the
progressive cerebral and peripheral circulatory impairments during aging and
Alzheimer’s disease.
years) but different cognitive impairment (i.e., MCI and AD of
increasing severity) and compared them to young and old (aged-
matched) controls. This integrative and comprehensive approach
to vascular changes in AD showed changes in NO bioavailability
and cortical, extracranial, and peripheral circulation in patients
with AD and suggested that they are directly associated with AD
and not to aging (Figure 6).
Evidence That Cortical Circulation Is
Impaired in Parallel to AD Severity
Although the traditional “amyloid cascade hypothesis” proposed
by Hardy and Higgins (Hardy and Higgins, 1992) indicates
cortical deposition of Aβ fragments, neurofibrillary tangles
and reactive microgliosis as the hallmark of AD, converging
evidence underscores the importance of other pathogenetic
mechanisms in AD, including oxidative stress, inflammation,
and mitochondrial dysfunction (Swerdlow, 2011; Zenaro et al.,
2016). In this multifaceted scenario, has germane the hypothesis
that vascular dysfunction in the cortex plays a key role in AD
pathophysiology (De La Torre, 2010). Specifically, impairment
of cortical perfusion appears to be highly correlated to AD
onset, implicating a pivotal role of vascular dysfunction and
CAA. The recent development in MRI techniques led to ASL,
a new advanced and non-invasive approach to brain perfusion
measurement, coupled with more precise post-processing
analysis. Our data are in agreement with and extend previous
knowledge in this field (Detre et al., 1992), indicating that cortical
hypoperfusion is not only associated with the presence of AD, but
most important, is well correlated with the severity of dementia,
NO bioavailability, and systemic vascular dysfunction (Figures 1,
5). The relevance of this result is particularly important because
current biomarkers of AD, such as cerebrospinal fluid tau/Aβ
fragments and positron emission tomography amyloid imaging,
are known to change non-linearly throughout the progression
of AD (Jack et al., 2013). We may speculate that cognitive
impairment might be more related to cortical perfusion, while
Aβ deposition takes place in the early/preclinical phases of AD. If
confirmed in longitudinal studies, this hypothesis might indicate
new therapeutic strategies for AD.
Evidence That ICA Blood Flow Is Impaired
in Parallel to AD Severity
Indeed, most of the literature related to circulatory dysfunction
associated with AD was focused on the cortical areas, which are
primarily affected in AD (Du et al., 2006). Our data (Figures 2, 3)
are in agreement with recent reports of a coupling between
cortical hypoperfusion and a reduction of blood flow from ICA
(Maalikjy Akkawi et al., 2003; Liu et al., 2014; Clark et al.,
2017), and highlight that AD-related circulation impairment
is not confined to the cortex, but is more likely the effect
of a systemic vascular dysfunction (De La Torre, 2009, 2010).
Moreover, the recognition of ICA blood flow reduction in parallel
to AD severity implies an exacerbated cortical hypo perfusion
in this population. These findings suggest that cortical perfusion
changes measured via ASL are strongly dependent on abnormal
inflow from extracranial arteries (Clark et al., 2017).
Evidence That Peripheral Vascular
Function Is Impaired in Parallel to AD
Severity
Along with cortical alteration of blood flow, few studies reported
evidence that peripheral vascular dysfunction determined
by ankle-to-brachial index, flow-mediated dilation, intima-
media thickness, and endothelial microvascular response to
acetylcholine are associated with AD (Dede et al., 2007; Khalil
et al., 2007; Laurin et al., 2007; Tachibana et al., 2016).
This literature suggests that systemic vascular impairments are
determined byAD, or from a different point of view, that systemic
vascular dysfunctionsmay trigger AD (De La Torre, 2004). In this
complex cause-effect scenario, the peripheral vascular difference
between the vascular dementia and AD has been accounted, and
AD appears, per se, to be associated with a significant reduction
of systemic vascular function. Data from the current study
(Figures 3–5) confirm this view and extend the relationship
between AD onset and circulatory impairment up to the more
advanced phases of the disease.
Evidence That Depletion in NO
Bioavailability Is Correlated With
Reduction of Cortical, Extracranial, and
Peripheral Blood Flow
Nitric oxide, an unstable free radical endogenously synthesized
by several cell-types, exerts various biological regulatory
functions at peripheral level in the nervous and cardiovascular
systems (Loscalzo and Welch, 1995; Calabrese et al., 2007).
Indeed, depletion of NO and endothelial nitric oxide synthase
enzymatic activity, as a major endogenous source of NO, are one
of themechanisms in the pathogenesis of endothelial dysfunction
in both cerebral and peripheral blood vessels (Katusic and Austin,
2014). Interestingly, recent literature has underlined the key role
Frontiers in Physiology | www.frontiersin.org 9 March 2018 | Volume 9 | Article 169
Venturelli et al. NO and Circulation in AD
of NOdepletion in the early stage of neurodegenerative disorders,
as well as in their progression (Katusic and Austin, 2014). In
a recent murine study, Merlini and coauthors (Merlini et al.,
2017) revealed that reduced NO bioavailability mediates cerebro-
arterial and peripheral dysfunction independently from CAA.
Interestingly, and similarly to the data retrieved in our human
model, endothelium-dependent vasorelaxation was significantly
impaired in both basilar and femoral arteries of 15-month-
old Swedish arctic (SweArc) transgenic AD mice compared
with that of age-matched wild-type and 6-month-old SweArc.
This vascular impairment was accompanied by significantly
reduced levels of cyclic GMP, demonstrating the central role
of NO bioavailability in the pathogenesis and development of
AD. Due to the transitory and unstable nature of this free
radical, several studies have determined the bioavailability of
NO via plasma levels of nitrite and nitrate (Casey et al., 2007,
2010). Interestingly, this literature indicates a strong positive
relationship between plasma level of nitrite and nitrate and
systemic vascular function (Casey et al., 2007, 2010). The present
data are in agreement with the above-mentioned animal and
human studies, and support the hypothesis that, in humans, the
depletion in NO bioavailability is correlated with reduction of
cortical, extracranial, and peripheral blood flow during aging and
in parallel to AD severity (Figures 4–6).
Other Physiological Considerations
The recent literature underlined that augmenting physical
activity and fitness can protect NO bioavailability, attenuating
the deleterious effects of advancing age on vascular function
(Groot et al., 2016). Therefore, particular attention on the
determination of the physical activity level is needed in order to
better describe the net effect of aging and AD to the systemic
vascular function. As expected, our results indicate that in
comparison to the YG, healthy elderly and patients with AD,
were more sedentary (Table 1). These data suggest that the
reduction of systemic vascular function and NO bioavailability
of these groups are likely affected by their low-level of physical
activity. However, it is important to note that the IPAQ values
amongOLD,MCI, AD1, AD2, and AD3were similar, implicating
that in these age-matched groups, aging and level of physical
activity are not responsible of the progressive reduction of NO
bioavailability and vascular dysfunction. Another physiological
factor important to mention in relation to the cerebral blood
flow assessment is the level of CO2. In fact, due to its
vasodilatory effect on the conduit intra- and extracranial arteries,
hypercapnia is routinely utilized for the evaluation of maximal
cerebral perfusion. Therefore, the determination of ExpCO2
is required in order to normalize the cerebral blood flow.
The data of resting ExpCO2 (Table 1) were similar in the 6
groups, implicating that ExpCO2 did not play a role in the
changes of cerebral blood flow in our subjects. Indeed, resting
blood flow to a specific organ is affected by its volume of
metabolically active tissue. As previously described in the text,
partial volume-corrected cortical and WM flow maps were
created for each subject, and FA and ICA blood flow were
normalized to leg muscle volume (thigh+ lower leg volume) and
total brain tissue volume (cortical, subcortical gray matter and
white matter volumes including the brainstem and cerebellum),
respectively (Liu et al., 2014; Venturelli et al., 2014). Indeed, basal
metabolism is another important physiological factor affected
by aging (Venturelli et al., 2013) and AD (Venturelli et al.,
2016), that may contribute to the resting blood flow changes
during aging and AD. Interestingly, our data of resting oxygen
uptake (Table 1) indicate similar basal metabolism in the six
groups of subjects, suggesting that this physiological factor is
not playing a direct role in the progressive changes of brain
and skeletal muscle blood flow. It is important to mention
that NO is a free radical playing several positive regulatory
functions at cellular and systemic level. However, it is well
established that elevated levels of free radicals have a plethora
of deleterious effects on the vascular and nervous system
during aging and AD, primarily associated with mitochondrial
dysfunction. Indeed, Sewrdlow and Khan (Swerdlow, 2011)
hypothesized the “mitochondrial cascade hypothesis” in AD,
whereby mitochondrial dysfunction accumulates over the disease
course, resulting in both symptoms and neuropathological
aspects of AD (Swerdlow et al., 2010). It is believed that
mitochondrial dysfunction precedes Aβ formation, increasing
reactive oxygen species (ROS) and oxidative stress, which, in
turn, may facilitate overproduction of Aβ (Morris et al., 2014).
In AD, mitochondrial damage is characterized by decreased
respiratory chain complexes activities, where complexes III and
IV are typically involved, causing ROS overproduction and
reduced ATP synthesis (Marques-Aleixo et al., 2012; Cadonic
et al., 2016; Pedrinolla et al., 2017). In this regard, brain tissues
are metabolically very active and are particularly susceptible to
the damaging effects by ROS. In case of AD, ROS have been
reported within those brain regions, such as the cerebral cortex
and hippocampus, which undergo selective neurodegeneration
(Bhat et al., 2015). Interestingly, a large body of evidence shows
that AD patients have oxidative metabolism dysfunction in both
the central nervous system (CNS) and peripheral tissues (i.e.,
vascular endothelial cells, platelets) suggesting that pathological
changes co-exist in brain and non-neural tissues (Morris et al.,
2014; Cadonic et al., 2016). Moreover, recent studies suggest
that mitochondria ROS overproduction contribute to accelerate
the development of the senescent phenotype in endothelial
cells, impairing regenerative and angiogenic capacity of the
endothelium, promoting atherosclerosis by altering the secretion
of cytokines, growth factors, and protease in the vascular wall
(Dai et al., 2012; El Assar et al., 2013).
Other potential confounding factors that may have influenced,
at least in part, our findings include the deconditioning due to
AD, the age-related aortic stiffness and progressive impairment
in diastolic heart functions (Pase et al., 2016).
AUTHOR CONTRIBUTIONS
MV performed the experiments, analyzed the data, prepared
the figures, and drafted the manuscript. APe performed the
experiments, analyzed the data, and drafted the manuscript.
IB performed the experiments, analyzed the data, and drafted
the manuscript. CF performed the experiments, analyzed the
Frontiers in Physiology | www.frontiersin.org 10 March 2018 | Volume 9 | Article 169
Venturelli et al. NO and Circulation in AD
data, and drafted the manuscript. NS interpreted the results
of experiments, and drafted the manuscript. ST performed the
experiments, interpreted the results of experiments, and drafted
the manuscript. EM performed the experiments, interpreted
the results of experiments, and drafted the manuscript.
LC performed the experiments, interpreted the results of
experiments, and drafted the manuscript. AS performed the
experiments, interpreted the results of experiments, and drafted
the manuscript. APi performed the experiments, interpreted
the results of experiments, and drafted the manuscript.
MR interpreted the results of experiments, and drafted the
manuscript. FP interpreted the results of experiments, and
drafted the manuscript. FS edited, revised, and approved the final
version of manuscript.
FUNDING
The study was supported by the grant 2010KL2Y73_004 awarded
to FS from the Italian Ministry for Research (PRIN 2010).
ACKNOWLEDGMENTS
We thank all the study participants and Dr. Scarsini R. for their
support and dedication to the research project.
REFERENCES
Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox,
N. C., et al. (2011). The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.03.008
Alsop, D. C., Detre, J. A., Golay, X., Gunther, M., Hendrikse, J., Hernandez-
Garcia, L., et al. (2015). Recommended implementation of arterial spin-labeled
perfusion MRI for clinical applications: a consensus of the ISMRM perfusion
study group and the European consortium for ASL in dementia. Magn. Reson.
Med. 73, 102–116. doi: 10.1002/mrm.25197
Appollonio, I., Leone, M., Isella, V., Piamarta, F., Consoli, T., Villa, M. L., et al.
(2005). The Frontal Assessment Battery (FAB): normative values in an Italian
population sample. Neurol. Sci. 26, 108–116. doi: 10.1007/s10072-005-0443-4
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi,
M. A., et al. (2015). Oxidative stress, mitochondrial dysfunction and
neurodegenerative diseases; a mechanistic insight. Biomed. Pharmacother. 74,
101–110. doi: 10.1016/j.biopha.2015.07.025
Booth,M. (2000). Assessment of physical activity: an international perspective. Res.
Q. Exerc. Sport 71(Suppl. 2), 114–120. doi: 10.1080/02701367.2000.11082794
Buxton, R. B., Frank, L. R., Wong, E. C., Siewert, B., Warach, S., and Edelman, R. R.
(1998). A general kinetic model for quantitative perfusion imaging with arterial
spin labeling.Magn. Reson. Med. 40, 383–396. doi: 10.1002/mrm.1910400308
Cadonic, C., Sabbir, M. G., and Albensi, B. C. (2016). Mechanisms of
mitochondrial dysfunction in Alzheimer’s disease. Mol. Neurobiol. 53,
6078–6090. doi: 10.1007/s12035-015-9515-5
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., and
Stella, A.M. (2007). Nitric oxide in the central nervous system: neuroprotection
versus neurotoxicity. Nat. Rev. Neurosci. 8, 766–775. doi: 10.1038/nrn2214
Casey, D. P., Beck, D. T., and Braith, R. W. (2007). Systemic plasma levels
of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses
in young men and women. Clin. Exp. Pharmacol. Physiol. 34, 1291–1293.
doi: 10.1111/j.1440-1681.2007.04715.x
Casey, D. P., Nichols, W. W., Conti, C. R., and Braith, R. W. (2010). Relationship
between endogenous concentrations of vasoactive substances and measures of
peripheral vasodilator function in patients with coronary artery disease. Clin.
Exp. Pharmacol. Physiol. 37, 24–28. doi: 10.1111/j.1440-1681.2009.05225.x
Clark, L. R., Berman, S. E., Rivera-Rivera, L. A., Hoscheidt, S. M., Darst, B. F.,
Engelman, C. D., et al. (2017). Macrovascular and microvascular cerebral blood
flow in adults at risk for Alzheimer’s disease. Alzheimers Dement. 7, 48–55.
doi: 10.1016/j.dadm.2017.01.002
Dai, D. F., Rabinovitch, P. S., and Ungvari, Z. (2012).
Mitochondria and cardiovascular aging. Circ. Res. 110, 1109–1124.
doi: 10.1161/CIRCRESAHA.111.246140
Dallaire-Theroux, C., Callahan, B. L., Potvin, O., Saikali, S., and Duchesne,
S. (2017). Radiological-pathological correlation in Alzheimer’s Disease:
systematic review of antemortem magnetic resonance imaging findings. J.
Alzheimers Dis. 57, 575–601. doi: 10.3233/JAD-161028
Dede, D. S., Yavuz, B., Yavuz, B. B., Cankurtaran, M., Halil, M., Ulger, Z.,
et al. (2007). Assessment of endothelial function in Alzheimer’s disease: is
Alzheimer’s disease a vascular disease? J. Am. Geriatr. Soc. 55, 1613–1617.
doi: 10.1111/j.1532-5415.2007.01378.x
De La Torre, J. C. (2004). Alzheimer’s disease is a vasocognopathy: a new term to
describe its nature.Neurol. Res. 26, 517–524. doi: 10.1179/016164104225016254
De La Torre, J. C. (2009). Cerebrovascular and cardiovascular
pathology in Alzheimer’s disease. Int. Rev. Neurobiol. 84, 35–48.
doi: 10.1016/S0074-7742(09)00403-6
De La Torre, J. C. (2010). The vascular hypothesis of Alzheimer’s disease: bench to
bedside and beyond. Neurodegener. Dis. 7, 116–121. doi: 10.1159/000285520
Detre, J. A., Leigh, J. S., Williams, D. S., and Koretsky, A. P. (1992).
Perfusion imaging. Magn. Reson. Med. 23, 37–45. doi: 10.1002/mrm.19102
30106
Du, A. T., Jahng, G. H., Hayasaka, S., Kramer, J. H., Rosen, H. J., Gorno-
Tempini, M. L., et al. (2006). Hypoperfusion in frontotemporal dementia and
Alzheimer disease by arterial spin labeling MRI. Neurology 67, 1215–1220.
doi: 10.1212/01.wnl.0000238163.71349.78
El Assar, M., Angulo, J., and Rodriguez-Manas, L. (2013). Oxidative stress
and vascular inflammation in aging. Free Radic. Biol. Med. 65, 380–401.
doi: 10.1016/j.freeradbiomed.2013.07.003
Folstein, M. F., Folstein, S. E., and Mchugh, P. R. (1975). “Mini-mental state”. A
practical method for grading the cognitive state of patients for the clinician. J.
Psychiatr. Res. 12, 189–198. doi: 10.1016/0022-3956(75)90026-6
Groot, H. J., Rossman, M. J., Garten, R. S., Wang, E., Hoff, J., Helgerud,
J., et al. (2016). The effect of physical activity on passive leg movement-
induced vasodilation with age. Med. Sci. Sports Exerc. 48, 1548–1557.
doi: 10.1249/MSS.0000000000000936
Hardy, J. A., and Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256, 184–185. doi: 10.1126/science.1566067
Herholz, K. (2011). Perfusion SPECT and FDG-PET. Int. Psychogeriatr. 23 (Suppl.
2), S25–S31. doi: 10.1017/S1041610211000937
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Perez, J. M., Evans,
A. C., and Alzheimer’s Disease Neuroimaging, I. (2016). Early role of vascular
dysregulation on late-onset Alzheimer’s disease based on multifactorial data-
driven analysis. Nat. Commun. 7:11934. doi: 10.1038/ncomms11934
Ives, S. J., Amann, M., Venturelli, M., Witman, M. A., Groot, H. J., Wray,
D. W., et al. (2016). The mechanoreflex and hemodynamic response to
passive leg movement in heart failure. Med. Sci. Sports Exerc. 48, 368–376.
doi: 10.1249/MSS.0000000000000782
Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W.,
Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer’s
disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol.
12, 207–216. doi: 10.1016/S1474-4422(12)70291-0
Katusic, Z. S., and Austin, S. A. (2014). Endothelial nitric oxide: protector of a
healthy mind. Eur. Heart J. 35, 888–894. doi: 10.1093/eurheartj/eht544
Khalil, Z., Logiudice, D., Khodr, B., Maruff, P., and Masters, C. (2007). Impaired
peripheral endothelial microvascular responsiveness in Alzheimer’s disease. J.
Alzheimers Dis. 11, 25–32. doi: 10.3233/JAD-2007-11106
Frontiers in Physiology | www.frontiersin.org 11 March 2018 | Volume 9 | Article 169
Venturelli et al. NO and Circulation in AD
Laurin, D., Masaki, K. H., White, L. R., and Launer, L. J. (2007). Ankle-to-
brachial index and dementia: the Honolulu-Asia aging study. Circulation 116,
2269–2274. doi: 10.1161/CIRCULATIONAHA.106.686477
Layec, G., Venturelli, M., Jeong, E. K., and Richardson, R. S. (2014). The validity of
anthropometric leg muscle volume estimation across a wide spectrum: from
able-bodied adults to individuals with a spinal cord injury. J. Appl. Physiol.
(1985) 116, 1142–1147. doi: 10.1152/japplphysiol.01120.2013
Liu, J., Zhu, Y. S., Khan, M. A., Brunk, E., Martin-Cook, K., Weiner, M. F., et al.
(2014). Global brain hypoperfusion and oxygenation in amnesticmild cognitive
impairment. Alzheimers Dement. 10, 162–170. doi: 10.1016/j.jalz.2013.04.507
Loscalzo, J., and Welch, G. (1995). Nitric oxide and its role in the cardiovascular
system. Prog. Cardiovasc. Dis. 38, 87–104. doi: 10.1016/S0033-0620(05)80001-5
Maalikjy Akkawi, N., Borroni, B., Agosti, C., Pezzini, A., Magoni, M., Rozzini,
L., et al. (2003). Volume reduction in cerebral blood flow in patients with
Alzheimer’s disease: a sonographic study. Dement. Geriatr. Cogn. Disord. 16,
163–169. doi: 10.1159/000071005
Maier, F. C., Wehrl, H. F., Schmid, A. M., Mannheim, J. G., Wiehr, S., Lerdkrai, C.,
et al. (2014). Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF
dynamics and connects vascular amyloidosis to quantitative loss of perfusion.
Nat. Med. 20, 1485–1492. doi: 10.1038/nm.3734
Marques-Aleixo, I., Oliveira, P. J., Moreira, P. I., Magalhaes, J., and Ascensao, A.
(2012). Physical exercise as a possible strategy for brain protection: evidence
from mitochondrial-mediated mechanisms. Prog. Neurobiol. 99, 149–162.
doi: 10.1016/j.pneurobio.2012.08.002
Mcdaniel, J., Fjeldstad, A. S., Ives, S., Hayman, M., Kithas, P., and Richardson, R.
S. (2010a). Central and peripheral contributors to skeletal muscle hyperemia:
response to passive limb movement. J. Appl. Physiol. (1985) 108, 76–84.
doi: 10.1152/japplphysiol.00895.2009
Mcdaniel, J., Hayman, M. A., Ives, S., Fjeldstad, A. S., Trinity, J. D., Wray, D. W.,
et al. (2010b). Attenuated exercise induced hyperaemia with age: mechanistic
insight from passive limb movement. J. Physiol. (Lond). 588, 4507–4517.
doi: 10.1113/jphysiol.2010.198770.
Mckhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr.,
Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers. Dement. 7, 263–269. doi: 10.1016/j.jalz.2011.03.005
Merlini, M., Shi, Y., Keller, S., Savarese, G., Akhmedov, A., Derungs, R.,
et al. (2017). Reduced nitric oxide bioavailability mediates cerebroarterial
dysfunction independent of cerebral amyloid angiopathy in a mouse model
of Alzheimer’s disease. Am. J. Physiol. Heart Circ. Physiol. 312, H232–H238.
doi: 10.1152/ajpheart.00607.2016
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and
scoring rules. Neurology 43, 2412–2414. doi: 10.1212/WNL.43.11.2412-a
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., and Burns, J. M.
(2014). Is Alzheimer’s disease a systemic disease? Biochim. Biophys. Acta 1842,
1340–1349. doi: 10.1016/j.bbadis.2014.04.012
Pase, M. P., Beiser, A., Himali, J. J., Tsao, C., Satizabal, C. L., Vasan, R. S., et al.
(2016). Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment
and Dementia. Stroke 47, 2256–2261. doi: 10.1161/STROKEAHA.116.013508
Pedrinolla, A., Schena, F., and Venturelli, M. (2017). Resilience to Alzheimer’s
disease: the role of physical activity. Curr. Alzheimer Res. 14, 546–553.
doi: 10.2174/1567205014666170111145817
Picano, E., Bruno, R. M., Ferrari, G. F., and Bonuccelli, U. (2014). Cognitive
impairment and cardiovascular disease: so near, so far. Int. J. Cardiol. 175,
21–29. doi: 10.1016/j.ijcard.2014.05.004
Reitz, C., Brayne, C., and Mayeux, R. (2011). Epidemiology of Alzheimer disease.
Nat. Rev. Neurol. 7, 137–152. doi: 10.1038/nrneurol.2011.2
Reitz, C., and Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic
criteria, risk factors and biomarkers. Biochem. Pharmacol. 88, 640–651.
doi: 10.1016/j.bcp.2013.12.024
Swerdlow, R. H. (2011). Brain aging, Alzheimer’s disease, and mitochondria.
Biochim. Biophys. Acta 1812, 1630–1639. doi: 10.1016/j.bbadis.2011.08.012
Swerdlow, R. H., Burns, J. M., and Khan, S. M. (2010). The Alzheimer’s disease
mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl. 2), S265–279.
doi: 10.3233/JAD-2010-100339
Tachibana, H., Washida, K., Kowa, H., Kanda, F., and Toda, T. (2016). Vascular
function in Alzheimer’s disease and vascular dementia. Am. J. Alzheimers Dis.
Other Demen. 31, 437–442. doi: 10.1177/1533317516653820
Trinity, J. D., Groot, H. J., Layec, G., Rossman, M. J., Ives, S. J., Runnels, S.,
et al. (2012). Nitric oxide and passive limb movement: a new approach to
assess vascular function. J. Physiol. 590, 1413–1425. doi: 10.1113/jphysiol.2011.
224741
Venturelli, M., Amann, M., Layec, G., Mcdaniel, J., Trinity, J. D., Fjeldstad,
A. S., et al. (2014). Passive leg movement-induced hyperaemia with a spinal
cord lesion: evidence of preserved vascular function. Acta Physiol. (Oxf). 210,
429–439. doi: 10.1111/apha.12173
Venturelli, M., Ce, E., Limonta, E., Muti, E., Scarsini, R., Brasioli, A., et al. (2016).
Possible predictors of involuntary weight loss in patients with Alzheimer’s
disease. PLoS ONE 11:e0157384. doi: 10.1371/journal.pone.0157384
Venturelli, M., Schena, F., Scarsini, R., Muti, E., and Richardson, R. S. (2013).
Limitations to exercise in female centenarians: evidence that muscular
efficiency tempers the impact of failing lungs. Age (Dordr). 35, 861–870.
doi: 10.1007/s11357-011-9379-1
Zenaro, E., Piacentino, G., and Constantin, G. (2016). The blood-brain barrier
in Alzheimer’s disease. Neurobiol. Dis. 107, 41–56. doi: 10.1016/j.nbd.2016.
07.007
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Venturelli, Pedrinolla, Boscolo Galazzo, Fonte, Smania,
Tamburin, Muti, Crispoltoni, Stabile, Pistilli, Rende, Pizzini and Schena. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Physiology | www.frontiersin.org 12 March 2018 | Volume 9 | Article 169
